Immunic (IMUX) Long-Term Debt Issuances (2024 - 2025)

Immunic (IMUX) posted Long-Term Debt Issuances of $55.9 million for Q4 2025, up 1081.39% sequentially from $4.7 million in Q2 2025.

Immunic (IMUX) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends

Immunic has reported Long-Term Debt Issuances for 2 years, with the latest figure at $55.9 million in Q4 2025.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $55.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $60.7 million (changed N/A YoY) and the FY2025 annual result came in at $60.7 million, changed N/A from the prior year.
Long-Term Debt Issuances rose to $55.9 million in Q4 2025 per IMUX's latest filing, from $4.7 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $74.3 million in Q1 2024 and troughed at -$74.3 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-675,522.58
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Immunic	682.77 Mn	682.77 Mn	-	-

Download Data